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ABSTRACT
Advanced glycation end-products (AGEs), which bind to type 1 collagen in bone and skin, have been implicated in reduced bone
quality. The AGE reader™ measures skin autofluorescence (SAF), which might be regarded as a marker of long-term accumulation
of AGEs in tissues. We investigated the association of SAF with bone mineral density (BMD) and fractures in the general population.
We studied 2853 individuals from the Rotterdam Study with available SAF measurements (median age, 74.1 years) and with data on
prevalent major osteoporotic (MOFs: hip, humerus, wrist, clinical vertebral) and vertebral fractures (VFs: clinical + radiographic Gen-
ant’s grade 2 and 3). Radiographs were assessed 4 to 5 years before SAF. Multivariate regressionmodels were performed adjusted for
age, sex, BMI, creatinine, smoking status, and presence of diabetes and additionally for BMD with interaction terms to test for effect
modification. Prevalence of MOFs was 8.5% and of VFs 7%. SAF had a curvilinear association with prevalent MOFs and VFs and there-
fore, age-adjusted, sex stratified SAF quartiles were used. The odds ratio (OR) (95% confidence interval [CI]) of the second, third and
fourth quartiles of SAF for MOFs were as follows: OR 1.60 (95% CI, 1.08–2.35; p = .02); OR 1.30 (95% CI, 0.89–1.97; p = .20), and OR 1.40
(95% CI, 0.95–2.10; p = .09), respectively, with first (lowest) quartile as reference. For VFs the ORs were as follows: OR 1.69 (95% CI,
1.08–2.64; p = .02), OR 1.74(95% CI, 1.11–2.71; p = .01), and OR 1.73 (95% CI, 1.12–2.73; p = .02) for second, third, and fourth quartiles,
respectively. When comparing the top three quartiles combined with the first quartile, the OR (95% CI) for MOFs was 1.43 (95% CI,
1.04–2.00; p = .03) and for VFs was 1.72 (95% CI, 1.18–2.53; p = .005). Additional adjustment for BMD did not change the associations.
In conclusion, there is evidence of presence of a threshold of skin AGEs below which there is distinctly lower prevalence of fractures.
Longitudinal analyses are needed to confirm our cross-sectional findings. © 2020 The Authors. Journal of Bone and Mineral Research
published by American Society for Bone and Mineral Research.
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Introduction
Advanced glycation end-products (AGEs) have been impli-cated in physiological mechanisms of aging and chronic
diseases related to aging, such as cardiovascular diseases, Alzhei-
mer’s disease, and complications of diabetes.(1,2) Although AGEs
have been shown to accumulate in bone, the role of AGEs is
not completely understood in osteoporosis, which is a major
contributor to morbidity in the aging population. AGEs are a
heterogeneous group of compounds formed as a result of
non-enzymatic glycation of proteins.(3,4) One such protein is
type 1 collagen, which constitutes approximately 90% of the
bone matrix proteins.(5) AGEs bind to collagen in bone and
develop crosslinking (pentosidine, versperlysine) and non-
crosslinking (carboxymethyl lysine [CML], carboxyethyl lysine)
modifications of collagen molecules.(6,7) Moreover, AGEs
interact with the receptor for advanced glycation end product
(RAGE) on bone cells to generate inflammatory and oxidative
mediators via nuclear factor κ-B (NF-κB).(8,9) Through these
mechanisms, AGEs have been implicated in impaired bone
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biomechanical properties and reduced bone quality, espe-
cially in subjects with diabetes, who have higher levels of
AGEs in bone and increased fracture risk despite normal bone
mineral density (BMD).(10–15)
Previous studies have reported a relationship between AGEs
measured in serum, urine, and bone and bone strength reduction
using different study designs. in vitro models, using bone samples
incubated in glycated versus non-glycated environment, have
demonstrated that non-enzymatic glycation of collagen leads to
reduced bone quality without altering the bone quantity.(1,12) Stud-
ies using bone tissue excised from hip fracture patients have
shown higher levels of the AGE pentosidine than hip osteoarthritis
patients.(16,17) Studies using serum and urine pentosidine have
shown either positive or no associations with fractures in subjects
without type 2 diabetes (non-T2DM) and with type 2 diabetes
(T2DM).(18–20) Serum CML has been reported to positively predict
incident hip fractures in two population based cohorts.(21,22) Last,
studies using serum CML or pentosidine have shown no
relation,(21) or negative association, with BMD.(23,24) Hence, incon-
sistent outcomes have been observed depending on the type
and localization of AGEs studied in association with the bone
parameters.
Several techniques, such as mass spectrometry and high-
performance liquid chromatography, have been employed to
measure AGEs in different body compartments, including serum,
urine, and tissues. However, there is currently no standardized
way tomeasure AGEs, and the extent towhich serumor urineAGEs
represent tissue AGEs is controversial.(25) A promising technique is
skin autofluorescence (SAF), which measures skin AGEs based on
their fluorescent properties.(26,27) It is a very quick, user-friendly,
and highly reproducible technique.(5) It is noteworthy that AGEs
bind to type 1 collagen in both skin and bone.(5) Studies using
human cadavers have shown that skin andbonepentosidine levels
per milligram of collagen are correlated with each other.(28) Addi-
tionally, skin AGEs measured by SAF have been associated with
reduced bonematerial strength index (BMSi) measured with refer-
ence point indentation, a potential measure of bone quality, in a
small cross-sectional study in postmenopausal women with
T2DM.(29) Thus, measuring AGE levels by means of SAF might be
a reflection of bone AGEs and a potential biomarker of bone
strength and fracture risk.
The relationship of skin AGEs with BMD and fracture risk in the
general population remains to be established. The aim of the
present study is to investigate the associations between SAF,
BMD, and prevalent fractures in a cohort of elderly people from
the general population including individuals with diabetes from
the Rotterdam study (RS).
Subjects and Methods
Study population
This cross-sectional analysis is a part of the RS, an ongoing
population-based, prospective cohort study. The RS was set up
in 1990 in the Ommoord district of the city Rotterdam. The study
population consists of three cohorts that were included in three
different periods: RS-I in 1990, RS-II in 2000, and RS-III in 2006.
The inhabitants above 55 years of age in RS-I and RS-II and above
45 years of age in RS-III were invited for inclusion. All participants
were examined at baseline and every 3 to 5 years at follow-up
examinations. The design and objectives of the study have been
extensively described.(30) The RS was approved by the institu-
tional review board (Medical Ethics Committee) of Erasmus
Medical Center. All participants in the present analysis provided
written informed consent to participate.
The participants of the RS with SAF measurement constitute
almost 40% of the total alive participants from that cycle. We
included 2853 participants from RS-I (6th follow-up, n = 705
[25%]), RS-II (4th follow-up, n = 1034 [36%]), and RS-III (2nd
follow-up, n = 1114 [39%]) with available SAF measurements.
We excluded participants with missing data on informed con-
sent, effective glomerular filtration rate (eGFR), BMI, smoking sta-
tus, and diabetes status (Supplemental Fig. 1).
Measurement of SAF
The AGE Reader™ (DiagnOptics Technologies B.V., Groningen,
The Netherlands) was introduced in the RS in 2013 to measure
SAF noninvasively. SAF value measured by the AGE Reader has
a moderately strong correlation with the amount of AGEs mea-
sured in skin biopsies.(26,27) The device exploits the fluorescent
properties of AGEs. Skin fluorescence has also been evaluated
as a clinical tool for noninvasive assessment of AGEs in tissues
and associated with long-term complications of diabetes.(31,32)
Participants were instructed not to apply any lotion or creams
on the dominant forearm for 2 days prior to the measurement.
The AGE Reader illuminates 4 cm2 of skin on the dominant fore-
arm with an excitation light source with a peak wavelength at
370 nm.(27) Emission light with the wavelength of 420 to
600 nm and reflected excitation light with a wavelength of
300 to 420 nm from the skin is measured by the AGE reader.
AGE Reader software has been programmed to automatically
estimate SAF based on the ratio of emitted and reflected light
spectrums. Our AGE Reader, based on a validated algorithm, cor-
rects for skin reflectance between 6% and 10% and excludes par-
ticipants with a skin reflectance less than 6% (darker-skinned
individuals). Values were defined as outliers in SAF and excluded
from the analysis if they exceeded the scope of mean + 4SD;
based on this, eight participants were excluded.
Prevalent major osteoporotic fractures
Fracture events that occurred after the age of 45 years for RS-III and
after the age of 55 years for RS-I and RS-II were included until the
end of 2012. All fracture events were reported by general practi-
tioners in the research area by means of computerized systems
and by research physicians or trained nurses outside the research
area or through hospital records. All events reported were verified
by research physicians who independently reviewed and coded
the information. Subsequently, a medical expert reviewed all
inconsistencies in coded events for final classification.
Fractures were included if they are a component of major oste-
oporotic fractures (MOFs), which includes fracture of the hip, verte-
bra (clinical), wrist, or humerus. These fractures are the basis for the
10-year absolute fracture risk estimates via the Fracture Risk
Assessment Tool (FRAX) used in multiple large-scale clinical stud-
ies.(33) Clinical vertebral fractures were defined as those that came
to medical attention when subjects with symptoms (mainly back
pain) visited the medical practitioner and confirmation of fractures
occurred on spine radiographs. All fractures were coded according
to the International Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10).
Radiographic vertebral fractures
All thoracolumbar radiographs were obtained by a digitalized
Fuji FCR system (FUJIFILM Medical Systems, Stanford, CA, USA)
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according to a standardized protocol described elsewhere.(34)
Radiographic vertebral assessment data was available for 2085
subjects with available SAF measurements till the end of 2008.
Vertebral fractures were classified using vertebral morphometry
grading 1 to 3 (OPTASIA-Spina Analyzer; Optasia Medical, Chea-
dle, UK).(35) Because there is doubt whether grade 1 (mild) defor-
mities represent true osteoporotic vertebral fractures or not, we
considered grade 2 (moderate) and grade 3 (severe) fractures as
radiographic vertebral fractures.(36)
Prevalent vertebral fractures
For this study, prevalent vertebral fractures (VFs) were defined as
a combination of any vertebral fracture identified on either a
radiograph as grade 2 (moderate) or grade 3 (severe) deformity
or a clinically reported spine fracture. Therefore, we performed
analyses on the most clinically relevant vertebral fractures.(36)
Measurement of BMD
BMD was measured at the femoral neck (FN) and lumbar spine
(LS) using iDXA Prodigy total body fan-beam densitometer
(GE Lunar Corp., Madison, WI, USA) as reported here.(30) All scans
were performed and verified by a trained technician who applied
adjustments when necessary. Sex-specific T-scores for FN and LS-
BMD were calculated using the Third National Health and Nutri-
tion Examination Survey (NHANES III) reference population.(37) A
total of 2654 participants (missing = 199) had complete data on
FN-BMD and LS-BMD. The subjects from the cohort RS-I (6th
follow-up, n = 624 or 24%) and RS-II (4th follow-up, n = 978 or
36%) underwent BMD scanning on average 4 to 5 years before
SAF measurements. RS-III (2nd follow-up, n = 1052 or 40%) had
cross-sectional measurements of both FN-BMD and LS-BMD.
Measurement of trabecular bone score
Trabecular bone score (TBS) was analyzed using TBS iNsight soft-
ware (Med-Imaps, Geneva, Switzerland). Briefly, TBS is a novel
gray-level texture measurement, extracted from DXA images,
which correlates with 3D parameters of bone microarchitecture,
connectivity density, trabecular separation, and trabecular num-
ber. For each region of measurement, TBS was evaluated based
on gray-level analysis of the DXA images as the slope at the ori-
gin of the log–log representation of the experimental variogram.
The method of TBS assessment has been described in detail
elsewhere.(38)
A total of 2654 participants had complete data on TBS derived
from the same DXA images from which BMD was measured. We
performed our analysis on 2583 participants after excluding
those with a BMI above 37 as TBS calculations are not reliable
in those obese subjects.
Assessment of associated factors
Height (cm) and weight (kg) were measured in the research cen-
ter with the individuals in standing position wearing indoor
clothing without shoes. BMI was computed as weight in kilo-
grams divided by height in meters squared (kg/m2). T2DM was
defined by combining information on antidiabetic medication
use, fasting blood glucose levels, or diagnosis in the GP registries.
Smoking status was classified as current, ex- or never smokers
collected through self-report during home interviews.
Biochemistry
Serum creatinine and serum fasting glucose were measured
through automated enzymatic method. eGFR was calculated
by the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation using serum creatinine concentration, age,
and sex data.(30)
Statistical methods
Statistical analyses were performed through IBM SPSS statistics
24 (version 24.0; IBM Corp., Armonk, NY, USA). Normality of data
was determined by the use of histograms and Shapiro-Wilk test.
Depending on the normal or non-normal distribution, data is
presented as mean  SD or median (interquartile range, IQR),
respectively. Means of continuous variables among groups were
compared via the use of Mann-Whitney-Wilcoxon test when a
non-normal distribution was assumed or independent samples
t test or ANOVA when the variable was normally distributed.
Chi-square test was adopted to compare the means of categori-
cal variables.
We identified potential confounders in the relationship
between exposure (SAF) and outcome (BMD/TBS/fractures)
based on literature evidence. Age, sex, BMI, eGFR, smoking sta-
tus, diabetes status, and RS cohorts were included as covari-
ates to study these relationships and consistently used in
fully adjusted models. Linear regression analysis was used to
assess the relationship between SAF and BMD at the LS and
FN and SAF and TBS. In linear regression analysis, all models
included a time variable taking into account the difference in
years, if any, between SAF and BMD/TBS measurements. Logis-
tic regression analysis was performed to assess whether SAF
was associated with the presence of prevalent VFs or MOFs.
A centered linear (cSAF) and polynomial term (cSAF2) was
added to the logistic regression model to check for the curvi-
linear effects between SAF and fractures (Supplemental
Table 1a and b). A comparison of linear versus polynomial
model in studying the association of SAF and MOFs using
Akaike information criterion (AIC) (1672.8 versus 1664.5) and
−2log-likelihood (−2LL) (1515.2 versus 1505.6) and for SAF
and VFs with AIC (1384.2 versus 1375.0) and −2LL (1410.6 ver-
sus 1402.7) showed that a polynomial model provides a better
fit to the data. Although a polynomial model fitted best to
study this relation, we still studied SAF in quartiles to allow
for a better comparison with the existing literature and for eas-
ier interpretation of our results.
Henceforth, sex-stratified, age-adjusted SAF scores were cal-
culated for the total population, because SAF and fractures are
strongly affect by age and sex.(39,40) Next, we classified individ-
uals into quartiles of their age-adjusted SAF scores, in men: first
quartile (Q1) SAF ≤ −0.68, second quartile (Q2) −0.68 < SAF <
−0.12, third quartile (Q3) −0.12 < SAF < 0.58, and highest quar-
tile (Q4) SAF ≥0.58; in women: first quartile Q1 SAF ≤ −0.71, sec-
ond quartile Q2 − 0.71 < SAF < −0.09, third quartile Q3 –
0.09 < SAF < 0.59, and highest quartile Q4 SAF ≥0.59.
We tested for interaction terms between SAF and diabetes
status, smoking status, eGFR, and sex in the multivariate fully
adjusted models, and report results separately where statistically
significant (p for interaction ≤ .10 for each) interactionwas found.
Because AGEs have been repeatedly implicated in pathogenesis
of increased fracture risk in T2DM,(13) we performed sensitivity
analyses in participants with and without T2DM irrespective of
statistical interaction.
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Results
General characteristics
Table 1 shows baseline characteristics of study participants by
quartiles of sex-stratified, age-adjusted SAF. There were gener-
ally no significant differences in baseline characteristics across
quartiles of SAF (all p > .05) except that an increasing prevalence
of T2DM subjects (p value for trend = .01) and current smokers
(p value for trend = .05) were observed from the first to the fourth
quartile. There was no significant increasing or decreasing trend
for the bone parameters, namely FN-BMD, LS-BMD, or TBS, from
the first to the fourth quartile. The prevalence of MOFs from the
first quartile to the fourth quartile did not show an increasing
trend (p value for trend = 0.27). The third quartile of SAF
(Q3) had significantly lower number of MOFs than Q2 and Q4.
The prevalence of VFs increased significantly from Q1 to Q4
(p value for trend = .02).
For the total study population, the median age was 74.1 years
(IQR, 66.9 to 81.1 years) and the mean value of SAF was
2.33  0.53 arbitrary units (A.U.). A total of 254 participants
(8.5%) had a prevalent MOF at the time of SAF measurements
including 80 clinical vertebral, 26 hip, 123 wrist, and 39 humerus
fractures. A total of 193 participants (7%) had a prevalent VF at
the time of analysis. A comparison of the basic demographics
between T2DM and non-T2DM subjects showed that participants
with T2DM were older, had higher BMI, were more often males,
and their SAF values were higher than participants without
T2DM (2.57  0.50 A.U. versus 2.36  0.47 A.U.). A comparison
of bone parameters showed that subjects with T2DM had higher
BMD at both FN (0.922  0.14 versus 0.899  0.13, p = .003) and
LS (1.18  0.20 versus 1.13  0.21, p < .001) than those without
T2DM but no difference in prevalence of MOFs and VFs.
Linear regression analysis of SAF with BMD and TBS
Table 2 shows the results of the linear regression analysis
describing the association of SAF with FN-BMD and LS-BMD.
There was a weak but statistically significant correlation coeffi-
cient between FN-BMD and SAF (r = −0.033; p = .09) as well as
between LS-BMD and SAF (r = 0.096; p < .001) in an unadjusted
model. This association attenuated after controlling for age and
sex for FN-BMD (β = −0.016; p = .39) as well as LS-BMD
(β = 0.037; p = .06) and totally disappeared in fully adjusted
models (FN-BMD: β = −0.021, p = .29; LS-BMD: β = 0.014, p = .47).
In fully adjusted linear regression models, there was a differ-
ence by sex in the association between SAF and BMD (p value
for interaction for SAF*sex for FN-BMD: .003, and for LS-BMD:
.05). After stratification by sex, there was a marginally significant
negative association of SAF with FN-BMD only in females
(β =−0.051; p = .04) in a fully adjusted model. On the other hand,
there was no association between LS-BMD and SAF in either of
the sexes.
Table 2 also shows the results of linear regression analysis
describing the association of SAF with TBS. In unadjusted
model, the correlation coefficient was marginally significant
(β = −0.38; p = .05). The association between SAF and TBS
(β = −0.36; p = .07) was minimally attenuated after adjusting
for age and sex, and totally disappeared after adjusting for
eGFR, smoking, diabetes status, and BMI (β = −0.26; p = .19).
There was no effect modification by sex or diabetes status
(all p > .10).
Logistic regression analysis for the prevalence of fractures
across sex-stratified, age-adjusted SAF quartiles
At the time of SAF measurement, there were 245 participants
with prevalent MOFs and 193 participants with prevalent VFs.
The analysis was performed consistently including the sex strat-
ified, age-adjusted SAF quartiles as a predictor in every model,
and fractures, either MOFs or VFs as outcome. Figure 1A and 1B
shows the results of logistic regression describing the association
between SAF quartiles and the presence of MOFs or VFs in fully
adjusted models including age, sex, BMI, smoking, RS cohorts,
diabetes status, and eGFR.
Table 1 Baseline Characteristics of Rotterdam Study Participants Categorized by Age-Adjusted, Sex-Stratified SAF Quartiles
Quartile 1 (n = 714) Quartile 2 (n = 713) Quartile 3 (n = 713) Quartile 4 (n = 713) pa
SAF (A.U.), mean  SD 1.88  0.23 2.18  0.18 2.5  0.19 3.0  0.36 NA
Males, n (%) 310 (43) 309 (43) 309 (43) 310 (43) NA
Age (years), median (IQR) 75.2 (14.2) 72.6 (15.3) 73.2 (14.1) 74.8 (13.0) <.001
BMI (kg/m2), mean  SD 27.2  3.8 27.3  4.1 27.8  4.5 27.9  4.8 .03
eGFR (mL/min), median (IQR) 78.9 (18.0) 80.5 (20.6) 78.8 (19.4) 78.0 (23.1) .05
T2DM (%) 8.4 10.5 14.8 20.8 <.001
Smoking status (%) <.001
Current 10 14 14 24
Past 51.5 54 57 49
Never 38.5 32 29 27
FN-BMD (g/cm2), mean  SD 0.903  0.134 0.907  0.138 0.907  0.136 0.892  0.131 .10
FN-BMD T-score, mean  SD −1.19  0.86 −1.17  0.88 −1.17  0.85 −1.27  0.82 .12
LS-BMD (g/cm2), mean  SD 1.134  0.206 1.113  0.204 1.147  0.196 1.144  0.216 .45
LS BMD T-score, mean  SD −0.43  1.62 −.45  1.60 −0.31  1.58 −0.38  1.67 .42
TBS, mean  SD 1.312  0.097 1.312  0.097 1.310  0.099 1.305  0.103 .26
MOFs, n (%) 53 (7) 66 (9.5) 58 (9) 68 (9.5) .27
VFs, n (%) 34 (5) 50 (7) 53 (7) 56 (8) .02
aValues of p < .05 are considered significant and are shown in bold.
A.U. = arbitrary units; BMI = bodymass index; FN-BMD = femoral neck bonemineral density; LS-BMD = lumbar spine bonemineral density; MOF =major
osteoporotic fracture; NA = not applicable; SAF = skin autofluorescence; TBS = trabecular bone score; VF = vertebral fractures.
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In a fully adjustedmodel, the ORs (95% CI, p value) of the second,
third, and fourth (highest) quartiles of SAF were 1.60 (95% CI,
1.08–2.35; p = .02), 1.33 (95% CI, 0.89–1.97; p = .16), and 1.41
(95% CI, 0.95–2.10; p = .08), respectively, when the bottom quar-
tile with lowest SAF values was used as reference (Fig. 1A). The
corresponding ORs (95% CI; p value) of the top three quartiles
Table 2 Association of SAFWith Femoral Neck and Lumbar Spine BMD and TBS in the Whole Population and Stratified by Sex (n = 2654)
Model 1 Model 2 Model 3
Parameter Standardized coefficient β p Standardized coefficient β p Standardized coefficient β p
Femoral neck BMDa
All −0.033 .09 −0.016 .39 −0.021 .29
Females −0.081 .002 −0.059 .02 −0.051 .04
Males −0.022 .45 0.002 .83 0.004 .69
Lumbar spine BMDa
All 0.096 <.001 0.037 .06 0.014 .47
Females 0.011 .68 0.022 .40 −0.005 .81
Males 0.054 .08 0.047 .15 0.026 .45
TBS
All −0.038 .05 −0.036 .07 −0.026 .19
Values are shown as standardized coefficient β per arbitrary unit and p value. Bold values are significant at p ≤ .05. Model 1 = unadjusted; model
2 = adjusted for age (and sex if non-stratified by sex); model 3 = additionally adjusted for DM status, BMI, creatinine, smoking, RS cohorts, and time
variable.
A.U. = arbitrary units; BMI = bodymass index; FN-BMD= femoral neck bonemineral density; LS-BMD = lumbar spine bonemineral density; MOF =major
osteoporotic fracture; NA = not applicable; SAF = skin autofluorescence; TBS = trabecular bone score; VF = vertebral fractures.
aValue of p for interaction for SAF*sex is 0.003 for FN-BMD, 0.05 for LS-BMD, and 0.55 for TBS; p < .10 is used for stratification.
Fig 1 (A) Odds ratio for prevalent major osteoporotic fractures by sex-stratified, age-adjusted quartiles of SAF levels adjusted for age, sex, BMI, smoking,
eGFR, RS cohorts, and diabetes status. (Note that SAF Q1 with the lowest value of SAF is the reference). (B) Odds ratio for prevalent radiological vertebral
fractures by sex-stratified, age-adjusted quartiles of SAF levels adjusted for age, sex, BMI, smoking, eGFR, RS cohorts, and diabetes status. (Note that SAF
quartile 1 with the lowest value of SAF is the reference). Q = quartile; SAF = skin autofluorescence.
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combined for MOFs was 1.43 (95% CI, 1.04–2.00; p = .03) versus
the bottom quartile of SAF (Fig. 1B).
Prevalent VFs
In a fully adjustedmodel, the ORs (95% CI; p value) of the second,
third, and fourth (highest) quartile of SAF were 1.65 (95% CI,
1.08–2.65; p = .03), 1.70 (95% CI, 1.11–2.71; p = .02), and 1.70
(95% CI, 1.12–2.73; p = .02), respectively, when the bottom quar-
tile was used as reference (Fig. 1B). The corresponding OR (95%
CI; p value) of the top three quartiles combined for VFs was
1.73 (95% CI, 1.18–2.53; p = .005) versus the bottom quartile of
SAF (Fig. 1B).
Logistic regression in subjects with available BMD measurements
FN-BMD and LS-BMD were available in a subset of 2654 partici-
pants. In logistic regression models for the subcohort with avail-
able BMD measurements, the association of higher SAF levels
with MOFs was no more statistically significant due to loss of
power (n = 199 missing BMD data), but the effect size did not
change with or without addition of either FN-BMD or LS-BMD
(Table 3). The association of higher SAF values with VFs was,
however, not attenuated by the addition of either FN-BMD or
LS-BMD, but was still statistically significant (Table 3).
Sensitivity analysis
Subgroup analysis was performed in predefined strata of T2DM
and non-T2DM and if the p value of interaction term was ≤ .10
for a particular interaction with SAF. First, the association of
SAF with MOFs in subjects with T2DM show the same nonlinear
trend and higher odds (p = n.s. [nonsignificant]) than in subjects
without T2DM, but no such trend was observed for the associa-
tion between SAF and VFs in those with T2DM (Table 4, Supple-
mental Table 2). Second, there was a statistically significant effect
modification in the relationship of SAF and MOFs by sex and
smoking (p value of interaction < .001 and = .01, respectively),
but not for VFs. After stratification by sex, there was a statistically
significant association only in females with OR 1.63 (95% CI,
1.11–2.40; p = .01) versus males with OR 1.02 (95% CI,
0.55–1.91; p = .95) for the association between SAF and MOFs
(Table 4). After stratification by smoking categories, there was a
significant association observed only in never smokers but not
in current or past smokers for the association between SAF and
MOFs with OR 2.53 (95% CI, 1.40–2.57; p = .002) versus OR 0.75
(95% CI, 0.25–2.23; p = .61) and OR 1.05 (95% CI, 0.68–1.62;
p = .82), respectively (Supplemental Table 3).
Discussion
In this population-based study we showed that SAF, a novel non-
invasive biomarker of skin AGEs, was nonlinearly associated with
two types of prevalent fractures, namely MOFs and VFs, in the
general population. There was evidence for the presence of a
threshold value of SAF, below which a lower prevalence of frac-
tures was seen. Importantly, the association between SAF and
fractures was independent of BMD. Indeed, FN-BMD and LS-
BMD showed no association with SAF in the entire cohort, but
there was a significant interaction term with sex with a weak
but significant inverse association of SAF with FN-BMD only in
females.
A nonlinear relationship between skin AGEs and MOFs includ-
ing hip fractures was found. Higher serum CML, a frequently
studied AGE, was related to higher risk of incident hip fractures
in two longitudinal cohort-studies in elderly subjects.(21,41) In
one of these studies, in 3384 community-dwelling men aged
70 to 89 years, a nonlinear relation was found of CML with inci-
dent hip fractures, which is similar to our findings of a nonlinear
relationship of SAF with prevalent hip fractures.(41) Compared to
the other two cohorts with a longitudinal design, our subjects
were relatively younger with fewer prevalent hip fractures, but
we still observed the same trend (Table 5). Urinary pentosidine
was associated with incident long-bone and vertebral fractures
in a linear fashion in Japanese subjects (n = 765), but no associa-
tion was found in French (n = 396) postmenopausal
women.(20,42) It should be noted that the serum AGEs used in
these studies have different properties and may influence bone
through slightly different mechanisms. For example, pentosidine
mainly influences collagen crosslinking,(43) whereas CML is a
non-crosslinking adduct but a potent activator of receptor for
AGEs (RAGE).(44,45) SAF measured by the AGE Reader has a mod-
erately strong correlation to both pentosidine (r = 0.55, p < .001)
and CML (r = 0.55, p < .001) in skin(26) and may thus take both
crosslinking and non-crosslinking AGEs into account.
We also found evidence of presence of a SAF threshold for
their association with VFs. AGEs and vertebral fracture risk has
Table 3 Odds ratio (OR) of Top ThreeQuartiles Combined (Q2–Q4)
Versus the BottomQuartile (Q1) of SAF forMOF and VFs in the Sub-
set With Available BMD Measurements (n = 2654 out of 2853)
MOF (n = 220) VF (n = 183)
Parameter OR (95% CI) p OR (95% CI) p
Q2–Q4 versus
Q1 (Ref.)
1.32 (0.94–1.85) .11 1.71 (1.16–2.53) .007
Adding FN-BMD 1.30 (0.92–1.82) .14 1.70 (1.12–2.41) .009
Adding LS-BMD 1.30 (0.92–1.83) .14 1.73 (1.17–2.56) .007
Values are shown as ORs (95% CI) per arbitrary unit (A.U.). SAF groups
were based on age-adjusted SAF quartiles. Bold values are significant at
p ≤ .05.
A.U. = arbitrary units; FN-BMD = femoral neck bonemineral density; LS-
BMD = lumbar spine bone mineral density; MOF = major osteoporotic
fracture; SAF = skin autofluorescence; VF = vertebral fracture.
Table 4 Odds ratio (OR) of Top Three Quartiles Combined
(Q2–Q4) Versus the First (Lowest) Quartile (Q1) of SAF for MOF






models ORs (95% CI) p OR (95% CI) p
Non-T2DM 1.40 (0.99–1.97) .056 1.52 (0.91–2.53) .11
T2DM 2.23 (0.64–7.77) .21 0.57 (0.15–2.27) .43
Females 1.63 (1.11–2.40) .01 1.48 (0.91–2.41) .11
Males 1.02 (0.55–1.91) .95 2.15 (1.14–4.04) .02
Values are OR (95% CI) per arbitrary unit (A.U.). SAF groups were based
on age-adjusted SAF quartiles. Value of p for interaction: for MOFs:
SAF*DM = 0.39, SAF*sex < .001; for VFs: SAF*DM = .32, SAF*sex = .24.
A.U. = arbitrary units; CI = confidence interval; MOF = major osteopo-
rotic fracture; OR = odds ratio; Q = quartile; Ref. = reference; SAF = skin
autofluorescence; T2DM = type 2 diabetes mellitus; VF = vertebral
fracture.
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been studied primarily with pentosidine in humans. Shiraki and
colleagues(46) found the highest quartile of urinary pentosidine
to be significantly associated with incident vertebral fracture rate
in older females without T2DM, which is in line with what we
found in our population without T2DM. A study in young female
mice fed with a high-AGE diet for 6 months showed deteriora-
tion of vertebral microarchitecture and a decrease in fracture
resistance.(47) in vitro glycation studies, on biopsy specimens
from both living donors and cadavers, showed that cancellous
bone is more susceptible to non-enzymatic glycation than corti-
cal bone.(48,49) The more efficient glycation of bone matrix pro-
teins in cancellous bone is due to higher surface area to
volume ratio, which could have facilitated better accessibility of
the sugars to the matrix proteins. This could suggest that espe-
cially vertebral fracture risk might be increased with increasing
levels of AGEs in persons with increased serum glucose levels
such as in subjects with T2DM.
In contrast, we observed no associations and not even a
trend between SAF and VFs in subjects with T2DM, although
others did. Higher serum pentosidine has been associated with
prevalent vertebral fractures in elderly T2DM subjects.(18,19) Our
study differed from these studies in several aspects, namely:
(i) lower prevalence of VFs (7% versus 30%) in our diabetics;
and (ii) inclusion of participants with T2DM from general popu-
lation in our cohort versus those referred to hospital outpatient
clinics, implying more severe disease in the latter patients. We
recently reported in the RS that subjects with T2DM and VFs
have a higher mortality compared to those without T2DM and
VFs.(50) Hence, the absence of a positive association of SAF with
VFs in subjects with T2DM in our study might be explained by
selective survival apart from low power. A third difference is
the use of skin AGEs in our study versus serum AGEs, where skin
AGEs may more accurately represent the true tissue burden of
AGEs, whereas serum AGEs are more likely to fluctuate over
time. Prospective analyses, preferably using skin and serum
AGEs simultaneously are needed to further explore these
discrepancies.
Various circulating AGEs have been measured with different
techniques in the past, which makes the comparison among
those studies difficult.(51) Furthermore, the amount of circulating
AGEs is influenced by dietary AGEs intake and renal clearance.(52)
We cannot be certain that skin AGEs are a good reflection of
bone AGEs, and bone turnover in the elderly might be much
higher than skin turnover. There is a lack of good studies com-
paring skin and bone AGEs at the same time because assessment
of AGE levels in bone requires invasive measures.(53) Moreover, a
recent study in CKD rats (n = 56) treated with an AGE breaker, ala-
gebrium, showed reduced total bone AGE content but no differ-
ence in bone pentosidine levels, which again points to the
heterogeneity in AGEs and limitations of measuring one AGE as
a representative of whole group.(54)
In sex-stratified analysis for fractures, there was an association
of SAF with MOFs only in women but not inmen, but no such dif-
ference for VFs. Notably in our cohort, the prevalence of MOFs in
women is four times higher than in men, which may partly
explain this difference. We also found a weak inverse association
between SAF and FN-BMD only in women independent of
potential confounders. Other studies also failed to show a strong
relation between AGEs and BMD or its surrogates.(21,23,29) We
suggest that potential sex-differences between AGEs accumula-
tion and bone strength measures should be studied in prospec-
tive studies within well-powered cohorts. After stratified analysis
in current, past, and never smokers, SAF was associated with
MOFs only in never smokers, although smoking has been identi-
fied as a risk factor for higher skin AGEs accumulation,(40) which
was also observed in our cohort (data not shown). The fact that
we did not find an association between SAF and MOFs in
smokers might be related to selective survival and the fact that
smokingmay increase fracture risk throughmultiple othermech-
anisms than AGEs alone.(55)
There are various mechanisms through which AGEs might
deteriorate bone quality and increase fracture predisposition.
in vitro studies have demonstrated that binding of AGEs to RAGE
inhibits differentiation and enhance apoptosis of osteoblasts.(56)
A study using osteocyte-like cells found that AGEs stimulate the
expression of sclerostin and inhibit the expression of receptor
activator of NF-κB ligand (RANKL), suggesting a state of low bone
turnover.(57) AGE-modification of collagen fibers decreases their
degradability by the matrix metalloproteinases either by mask-
ing the cleavage site or by preventing unfolding of collagenmol-
ecules due to an extra AGEs crosslink.(58) AGEs also alter the
biomechanical properties of bone tissue by increasing non-
enzymatic crosslinking of collagen fibers, which results in poor
bone quality.(12,13) In summary, our data primarily suggest that
the influence of AGEs on fracture risk is not mediated by
low BMD.





Participants 3373 3384 2853
Males (%) 39.8 100 43
Age (years) 78 (68–102) 76.3 (74.2–79) 74.1 (66.9–81)
Data analysis Longitudinal Longitudinal Cross-sectional
Mean follow-up 9.2 years 8–11 years NA
AGEs measured CML CML Skin autofluorescence
Technique used to measure AGEs ELISA ELISA AGE reader






per quartile Hazard ratio
Fractures
per quartile Odds ratio
Q1 69 0.94 31 Ref. 5 Ref.
Q2 94 1.34 30 1.13 9 2.08
Q3 81 1.18 17 0.49 6 1.33
Q4 104 1.69 28 0.70 8 1.40
CML = Serum carboxymethyllysine; ELISA = enzyme-linked immunosorbent assay; NA = not available; Q = quartile; Ref = reference.
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In contrast to our expectations, SAF was not associated with
TBS, a recently developed 2D textural imaging technique related
to bone microarchitecture and derived from DXA images. TBS
has been shown by several but not all studies to predict fracture
risk largely independent of BMD.(59–61) Our results suggest that
AGEs reflect the material properties of bone independent of
TBS (reflectingmicroarchitecture). AGEs and TBS have been stud-
ied together only in one cross-sectional study (n = 112) that
found an inverse association between urinary pentosidine and
TBS in subjects with T2DM but not in those without T2DM.(62)
Because both AGEs and TBS have been closely related to bone
quality independently of BMD, more studies are needed on the
relation between AGEs, TBS, and bone quality.
There are several limitations of our study. As mentioned, AGE
levels in skin may not adequately reflect AGEs in bone, although
human cadaver studies have shown that the amount of pentosi-
dine per milligram of collagen in both skin and bone were quite
close to each other when compared to other tissues.(29) Another
limitation is that a few MOFs and VFs have occurred quite some
time before SAF was measured, which may have influenced the
true association with fractures. However, it has been demon-
strated that protein turnover is a major determinant of AGEs
accumulation in tissues where skin collagen has a long half-life
of 14.8 years.(63) This may point toward relatively stable values
of skin AGEs over a longer period of time, although we cannot
be sure that the half-life of AGEs on collagen in bone is similar
to that of skin. Another limitation is that no serum AGEs were
available for comparison with SAF. Although many AGE moieties
exist with a diverse range of characteristics, the AGE Reader is
only able to detect fluorescent AGEs as SAF, which was shown
to be positively correlated to nonfluorescent AGEs measured in
skin biopsies.(27) Because this is an observational study, we are
unable to prove causation and a time gap existed between our
outcome and exposure, whichmay have led to an imprecise esti-
mation of the true association. Despite the availability of many
confounders we cannot exclude the existence of residual con-
founding. Also our data are not generalizable to the non-Dutch,
non-white, or younger population.
In conclusion, we found a positive association between skin
AGEs measured as SAF using the AGE Reader and prevalence
of both VFs and MOFs with evidence for a nonlinear relation
and a threshold effect. SAFwas weakly and negatively associated
with BMD in women only and BMD did not explain the observed
associations with fractures. Further research with a longitudinal
study design is needed to assess the potential use of SAF in pre-
diction of fractures both in subjects with and without T2DM.
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